XTL Biopharmaceuticals Ltd. (TLV:XTLB)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
4.500
-0.200 (-4.26%)
Sep 11, 2025, 5:04 PM IDT
-4.26%
Market Cap40.54M
Revenue (ttm)1.64M
Net Income (ttm)-3.74M
Shares Out881.39M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume472,902
Average Volume800,317
Open4.700
Previous Close4.700
Day's Range4.500 - 4.700
52-Week Range0.063 - 10.100
Beta0.96
RSI52.57
Earnings DateAug 9, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 10
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.